AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06794385
Drug: dinoprostone vaginal delivery system
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.
Trial: NCT05107336
Drug: AZD2693
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injection of AZD2693, once per month.
Trial: NCT05107336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.
Trial: NCT06793982
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Trial: NCT06795620
Drug: Adipose tissue derived mesenchymal Stroma/stem Cells transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.
Trial: NCT06472219
Drug: Prednisolone 30 mg
RxNorm normalized name: prednisolone 30 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.
Trial: NCT06472219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This a tablet identical to prednisolone.
Trial: NCT05765877
Drug: WX-0593 Tablets
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
Trial: NCT06794957
Drug: AL8326 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/tablet;Oral administration, once daily.
Trial: NCT06788704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient recive placebo once daily early post turp
Trial: NCT06034470
Drug: Pivekimab Sunirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05648968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion, prepared from matching placebo
Trial: NCT06474455
Drug: SHR-9839 ；SHR-A2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-9839 combined with SHR-A2009
Trial: NCT06474455
Drug: SHR-9839 ； SHR-A1921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-9839 combined with SHR-A1921
Trial: NCT06281132
Drug: CKD-341, D956
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 1 tablet under fasting condition
Trial: NCT05495815
Drug: Indefinite SAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indefinite oral suppressive antibiotic therapy
Trial: NCT06245889
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: additional chemotherapy - neoadjuvant or adjuvant rescue
Trial: NCT06245889
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: additional chemotherapy - adjuvant rescue
Trial: NCT06245889
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adjuvant rescue
Trial: NCT05525416
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
Trial: NCT00000758
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06428903
Drug: ADC189 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
Trial: NCT06428903
Drug: ADC189 granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
Trial: NCT06428903
Drug: ADC189 180mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
Trial: NCT05278208
Drug: LUTATHERA® (Lutetium Lu 177 dotatate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
Trial: NCT05870995
Drug: CALGE-VEN- RIC-conditioning
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
Trial: NCT06796504
Drug: Disease-Modifying Therapies (DMTs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will continue treatment with standard of care disease-modifying therapies for he duration of the study.
Trial: NCT05414136
Drug: BAT1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids
Trial: NCT04958122
Drug: benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Trial: NCT05534750
Drug: Standard quadruple therapy arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms.
Trial: NCT04762641
Drug: ABL503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Trial: NCT06636500
Drug: CG001419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses
Trial: NCT06636227
Drug: Diclofenac 100mg
RxNorm normalized name: diclofenac sodium 100 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 100mg
Trial: NCT06636227
Drug: Diclofenac 75mg
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 75mg
Trial: NCT06636227
Drug: Diclofenac 50mg
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 50mg
Trial: NCT06636227
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT06204237
Drug: [89Zr]Zr-DFO-APAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
Trial: NCT04930445
Drug: Oxbryta® (voxelotor) 500mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
Trial: NCT05672784
Drug: standard analgesia (paracetamol and meloxicam)
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
Trial: NCT05494788
Drug: CardiolRx
RxNorm normalized name: CARDIOTEX RX TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutically produced Cannabidiol
Trial: NCT06010719
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),
Trial: NCT06794086
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens based on fluorouracil (5-FU), such as CAPOX with a 3-week cycle or mFOLFOX6/FOLFIRI/FOLFOXIRI with a 2-week cycle, may be combined with targeted therapy. During chemotherapy or chemoradiotherapy, optimal supportive care will be provided.
Trial: NCT06797401
Drug: RBD5044
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBD5044, active drug.
Trial: NCT06795204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative Control
Trial: NCT06572111
Drug: BI 1839100 (C-14) formulation 1
RxNorm normalized name: TRIOLEIN, 1-C-14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1839100 (C-14) formulation 1
Trial: NCT04607005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
Trial: NCT04607005
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive Standard of care as they are used to before entry in the study.
Trial: NCT06788158
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program in which 2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule diluted in 2 ml of lidocaine injectable solution in a 50 ml bottle (20 mg/ml) in a single application at 1 point, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
Trial: NCT06796517
Drug: Proteasome Inhibitor
RxNorm normalized name: Proteasome inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
Trial: NCT06796517
Drug: IMiD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
Trial: NCT06483880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the placebo, which will be starch tablets in the same dosage of albendazole.
Trial: NCT06794502
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine from butterfly pea flower decocta extract is used as an additional TB drug therapy regimen for active TB patients during the initiation phase of treatment for 2 months.
Trial: NCT06791993
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an inert placebo capsule that matches the probiotic capsule in size, shape, and color. The placebo will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
Trial: NCT02915198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo
Trial: NCT06793553
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
Trial: NCT05329623
Drug: JDQ443
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the participants will receive a single oral dose of JDQ443.
Trial: NCT06679140
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets
Trial: NCT04720183
Drug: GLPG3970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
Trial: NCT04998604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection subcutaneous
Trial: NCT06793150
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
Trial: NCT05819658
Drug: GV1001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT05819658
Drug: GV1001 0.56mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized peptide from hTERT
Trial: NCT05819658
Drug: GV1001 1.12mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized peptide from hTERT
Trial: NCT05794321
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
Trial: NCT06789549
Drug: epinephrine nasal drops
RxNorm normalized name: epinephrine Nasal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation
Trial: NCT06640933
Drug: BIIB091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05785624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per the schedule specified in the respective arms.
Trial: NCT04847544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally BID for up to 28 days.
Trial: NCT06291376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo via weight-based IV infusion.
Trial: NCT06793670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of saline solution of NaCl 0.9%
Trial: NCT06793371
Drug: Placebo to match CK-4021586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally
Trial: NCT05027230
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
Trial: NCT05048134
Drug: HRS2300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS2300 monotherapy
Trial: NCT05048134
Drug: HRS2300、 SHR-1316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS2300 combined with SHR-1316
Trial: NCT05048134
Drug: HRS2300、SHR-1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS2300 combined with SHR-1701
Trial: NCT05380427
Drug: CU-40101
RxNorm normalized name: Cu 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
Trial: NCT06494683
Drug: Pueraria lobata radix
RxNorm normalized name: Pueraria montana var. lobata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
Trial: NCT05473195
Drug: BVL-GSK098 9mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
Trial: NCT05919082
Drug: LEO 90100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
Trial: NCT05919082
Drug: Daivobet® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
Trial: NCT04637763
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy for lymphodepletion
Trial: NCT06653907
Drug: Levothyroxine Sodium (LT4) Tablets
RxNorm normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.
Trial: NCT06653907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.
Trial: NCT05183490
Drug: Rapidly generated virus specific T (R-MVST) cells
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg
Trial: NCT05993078
Drug: 0.9% NaCl 2000ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will undergo NS 2000ml intravenous infusion immediately after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
Trial: NCT05993078
Drug: 0.9% NaCl 200-400ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients receive an NS 200-400ml after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
Trial: NCT05252754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO, 1-2 hours prior to endoscopy.
Trial: NCT05252754
Drug: Rectal Indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
Trial: NCT05838131
Drug: Experimental: CAR-T cells Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological:~chimeric antigen receptor T cells
Trial: NCT06592417
Drug: JSKN016 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.